Detalhe da pesquisa
1.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Lancet
; 399(10323): 461-472, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065705
2.
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.
J Infect Dis
; 210(4): 545-57, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24652494
3.
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.
BMC Infect Dis
; 13: 435, 2013 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24041010
4.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Vaccine
; 41(11): 1875-1884, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36781334
5.
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Hum Vaccin Immunother
; 19(1): 2206359, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226504
6.
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.
Pediatr Infect Dis J
; 40(9): 856-863, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34117198
7.
Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14â¯weeks and 9â¯months of age.
Vaccine
; 38(3): 530-538, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31703934
8.
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial.
Pediatr Infect Dis J
; 39(1): e1-e10, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725115
9.
Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35â¯months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Vaccine
; 37(13): 1876-1884, 2019 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30558818
10.
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine.
Pediatr Infect Dis J
; 38(8): 866-872, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306399
11.
Immunogenicity and safety of a DTaP-IPV//PRP approximately T combination vaccine given with hepatitis B vaccine: a randomized open-label trial.
Bull World Health Organ
; 86(6): 443-51, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18568273
12.
Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
Hum Vaccin Immunother
; 14(3): 593-595, 2018 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28933626
13.
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons.
Lancet Child Adolesc Health
; 2(5): 338-349, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30169267
14.
A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Vaccine
; 33(46): 6360-5, 2015 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26348402
15.
Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.
Pediatr Infect Dis J
; 30(4): e56-62, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21278617